Form 8-K - Current report:
SEC Accession No. 0001213900-25-005957
Filing Date
2025-01-23
Accepted
2025-01-23 16:01:26
Documents
15
Period of Report
2025-01-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0228426-8k_bellevue.htm   iXBRL 8-K 40762
2 SECOND AMENDMENT TO PROMISSORY NOTES, DATED JANUARY 23, 2025, BETWEEN BELLEVUE L ea022842601ex10-1_bellevue.htm EX-10.1 12359
  Complete submission text file 0001213900-25-005957.txt   291573

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE blac-20250123.xsd EX-101.SCH 4416
4 XBRL DEFINITION FILE blac-20250123_def.xml EX-101.DEF 27730
5 XBRL LABEL FILE blac-20250123_lab.xml EX-101.LAB 38554
6 XBRL PRESENTATION FILE blac-20250123_pre.xml EX-101.PRE 26346
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0228426-8k_bellevue_htm.xml XML 8619
Mailing Address 10900 NE 4TH STREET, SUITE 2300 BELLEVUE WA 98004
Business Address 10900 NE 4TH STREET, SUITE 2300 BELLEVUE WA 98004 425-635-7700
Bellevue Life Sciences Acquisition Corp. (Filer) CIK: 0001840425 (see all company filings)

EIN.: 845052822 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41390 | Film No.: 25550057
SIC: 3841 Surgical & Medical Instruments & Apparatus
(CF Office: 08 Industrial Applications and Services)